EUVIMEDEUVIMED entdecken
Crossref

Optimization and Biological Evaluation of Novel 1 H -Pyrrolo[2,3- c ]pyridin Derivatives as Potent and Reversible Lysine Specific Demethylase 1 Inhibitors for the Treatment of Acute Myelogenous Leukemia

Hong Jiang, Cong Li, Na Li, Li Sheng, Jingkai Wang, Wei-Juan Kan, Yuelei Chen, Dongmei Zhao iD, Dong Guo iD, Yu-Bo Zhou, Bing Xiong iD, Jia Li und 1 weitere

Journal of Medicinal Chemistry · 2024

DOI: 10.1021/acs.jmedchem.4c02017 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Hong Jiang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Structure-Based Drug Design and Discovery of Ministry of Education, Shenyang Pharmaceutical University, 103 Wenhua Lu, Shenyang 110…. Hauptthemen laut MEDLINE: Histone Demethylases, Leukemia, Myeloid, Acute, Antineoplastic Agents, Cell Proliferation. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Program for Liaoning Innovative Research Team in University, Program for Innovative Research Team of the Ministry of Education.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lysine-specific demethylase 1 (LSD1) plays a vital role in the epigenetic regulation of various cancers, making it a promising therapeutic target for anticancer treatments. Herein, we designed and synthesized a novel series of 1H-pyrrolo[2,3-c]pyridin derivatives as potent LSD1 inhibitors. A detailed structure-activity relationship exploration was carried out to discover multiple derivatives with nanomolar enzymatic IC50 values. Further biological evaluation demonstrated that these compounds acted as selective and reversible LSD1 inhibitors. The representative compounds exhibited highly potent antiproliferative activity against both AML (MV4-11 and Kasumi-1) and SCLC (NCI-H526) cell lines. Additionally, they effectively activated CD86 mRNA expression in MV4-11 cells and induced differentiation of AML cell lines. Notably, the most promising compound 23e showed a favorable oral PK profile and effectively suppressed the tumor growth in an AML xenograft model. Overall, our medicinal chemistry efforts provide compound 23e as a lead compound for developing LSD1 inhibitors for the treatment of AML and other advanced malignancies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Histone DemethylasesLeukemia, Myeloid, AcuteAntineoplastic AgentsCell ProliferationHumansAnimalsStructure-Activity RelationshipCell Line, TumorMicePyrrolesPyridinesEnzyme InhibitorsXenograft Model Antitumor AssaysDrug Screening Assays, AntitumorMolecular Docking SimulationMolecular Structure

Substanzen

Histone DemethylasesKDM1A protein, humanAntineoplastic AgentsPyrrolesPyridinesEnzyme Inhibitors

Autor:innen und Institutionen

  • Key Laboratory of Structure-Based Drug Design and Discovery of Ministry of Education, Shenyang Pharmaceutical University, 103 Wenhua Lu, Shenyang 110016, P. R. China.
  • Department of Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, P. R. China.
  • State Key Laboratory of Chemical Biology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, P. R. China.
  • State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
  • Lingang Laboratory, Shanghai200031, China.
  • School of Physical Science and Technology, ShanghaiTech University, Shanghai200031, China.

ORCID-Profile: Dongmei Zhao, Dong Guo, Bing Xiong, Tongchao Liu

Förderung

  • National Natural Science Foundation of China
  • Program for Liaoning Innovative Research Team in University
  • Program for Innovative Research Team of the Ministry of Education

Zitieren

APA

Jiang, H., Li, C., Li, N., Sheng, L., Wang, J., Kan, W. J., Chen, Y., Zhao, D., Guo, D., Zhou, Y. B., Xiong, B., Li, J., & Liu, T. (2024). Optimization and Biological Evaluation of Novel 1 H -Pyrrolo[2,3- c ]pyridin Derivatives as Potent and Reversible Lysine Specific Demethylase 1 Inhibitors for the Treatment of Acute Myelogenous Leukemia. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c02017

Vancouver

Jiang H, Li C, Li N, Sheng L, Wang J, Kan WJ, et al. Optimization and Biological Evaluation of Novel 1 H -Pyrrolo[2,3- c ]pyridin Derivatives as Potent and Reversible Lysine Specific Demethylase 1 Inhibitors for the Treatment of Acute Myelogenous Leukemia. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.4c02017

BibTeX
@article{Jiang2024,
  author = {Jiang, Hong and Li, Cong and Li, Na and Sheng, Li and Wang, Jingkai and Kan, Wei-Juan and Chen, Yuelei and Zhao, Dongmei and Guo, Dong and Zhou, Yu-Bo and Xiong, Bing and Li, Jia and Liu, Tongchao},
  title = {Optimization and Biological Evaluation of Novel 1 H -Pyrrolo[2,3- c ]pyridin Derivatives as Potent and Reversible Lysine Specific Demethylase 1 Inhibitors for the Treatment of Acute Myelogenous Leukemia},
  journal = {Journal of Medicinal Chemistry},
  year = {2024},
  doi = {10.1021/acs.jmedchem.4c02017}
}
Kostenlos starten →